CY2011010I2 - Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους - Google Patents

Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Info

Publication number
CY2011010I2
CY2011010I2 CY2011010C CY2011010C CY2011010I2 CY 2011010 I2 CY2011010 I2 CY 2011010I2 CY 2011010 C CY2011010 C CY 2011010C CY 2011010 C CY2011010 C CY 2011010C CY 2011010 I2 CY2011010 I2 CY 2011010I2
Authority
CY
Cyprus
Prior art keywords
preparation
methods
macrocyclic analogs
macrocyclic
analogs
Prior art date
Application number
CY2011010C
Other languages
English (en)
Other versions
CY2011010I1 (el
Original Assignee
Eisai R&D Management Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2011010(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd filed Critical Eisai R&D Management Co., Ltd
Publication of CY2011010I1 publication Critical patent/CY2011010I1/el
Publication of CY2011010I2 publication Critical patent/CY2011010I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY2011010C 1998-06-17 2011-08-12 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους CY2011010I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (2)

Publication Number Publication Date
CY2011010I1 CY2011010I1 (el) 2014-04-09
CY2011010I2 true CY2011010I2 (el) 2014-04-09

Family

ID=22219026

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100530T CY1111516T1 (el) 1998-06-17 2011-06-01 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους
CY2011010C CY2011010I2 (el) 1998-06-17 2011-08-12 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100530T CY1111516T1 (el) 1998-06-17 2011-06-01 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Country Status (22)

Country Link
US (4) US6214865B1 (el)
EP (4) EP2277873B1 (el)
JP (1) JP4454151B2 (el)
KR (1) KR100798600B1 (el)
CN (1) CN1216051C (el)
AT (1) ATE502932T1 (el)
AU (1) AU762998B2 (el)
BE (1) BE2011C028I2 (el)
BR (1) BRPI9911326B8 (el)
CA (3) CA2632433C (el)
CY (2) CY1111516T1 (el)
DE (2) DE69943296D1 (el)
DK (1) DK1087960T3 (el)
FR (1) FR11C0038I2 (el)
HU (1) HU227912B1 (el)
IL (1) IL139960A0 (el)
LU (1) LU91854I2 (el)
NO (5) NO328280B1 (el)
NZ (1) NZ508597A (el)
PT (1) PT1087960E (el)
WO (1) WO1999065894A1 (el)
ZA (1) ZA200007159B (el)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
ATE502932T1 (de) 1998-06-17 2011-04-15 Eisai R&D Man Co Ltd Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
US20050171014A1 (en) * 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
PL219737B1 (pl) 2002-03-22 2015-07-31 Eisai R & D Man Co Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
WO2004105794A2 (en) * 2003-05-29 2004-12-09 Abbott Laboratories Continuous dosing regimen with abt-751
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
CN109180615A (zh) * 2004-06-03 2019-01-11 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) * 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
SG10201811715YA (en) 2007-10-03 2019-02-27 Eisai R&D Man Co Ltd Intermediates and methods for the synthesis of halichondrin b analogs
CA2720632C (en) * 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
UA103794C2 (en) 2009-03-30 2013-11-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Liposome composition
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
EP2420504B1 (en) * 2009-04-14 2014-01-15 Nissan Chemical Industries, Ltd. Method for producing tetrahydropyran compound and intermediate thereof
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
SG10201602147YA (en) 2011-03-18 2016-05-30 Eisai R&D Man Co Ltd Methods And Compositions For Predicting Response To Eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CA2857385A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
EP2791123B1 (en) 2011-12-16 2018-07-18 Sandoz AG Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
JP6300030B2 (ja) * 2011-12-29 2018-03-28 サンド アクツィエンゲゼルシャフト ２−（（２ｓ，３ｓ，４ｒ，５ｒ）−５−（（ｓ）−３−アミノ−２−ヒドロキシプロプ−１−イル）−４−メトキシ−３−（フェニルスルホニルメチル）テトラヒドロフラン−２−イル）アセトアルデヒド誘導体およびこれらを調製するためのプロセス
CN104334562A (zh) * 2012-03-30 2015-02-04 阿方拉研究股份有限公司 用于制备软海绵素b的大环c1-酮类似物的合成方法及其中有用的中间体
CA2892780A1 (en) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
US9650397B2 (en) 2013-05-15 2017-05-16 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
WO2014208774A1 (en) 2013-06-26 2014-12-31 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
CA2916537C (en) * 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
ES2787603T3 (es) 2013-11-04 2020-10-16 Eisai R&D Man Co Ltd Reacciones de macrociclación y productos intermedios útiles en la síntesis de análogos de halicondrina B
RU2676486C1 (ru) 2013-12-06 2018-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы, предназначенные для синтеза аналогов галихондрина b
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
SG11201609777SA (en) 2014-05-28 2016-12-29 Eisai R&D Man Co Ltd Use of eribulin in the treatment of cancer
WO2016003975A1 (en) * 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
BR112017002827B1 (pt) 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd Derivado de quinolina altamente puro e método para produção do mesmo
US10208058B2 (en) * 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US10945990B2 (en) * 2015-03-04 2021-03-16 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
CN107849057B (zh) 2015-05-07 2020-11-10 卫材R&D管理有限公司 用于合成软海绵素大环内酯的大环化反应及中间体和其他片段
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
KR20180107243A (ko) * 2016-02-12 2018-10-01 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린의 합성에서의 중간체 및 관련된 합성 방법
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
KR20190009326A (ko) 2016-05-26 2019-01-28 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그의 중간체의 제조방법
WO2018006031A1 (en) 2016-06-30 2018-01-04 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
KR20190082782A (ko) 2016-10-14 2019-07-10 머크 샤프 앤드 돔 코포레이션 요로상피암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US10836776B2 (en) 2016-11-23 2020-11-17 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN110139866B (zh) * 2017-01-02 2022-05-17 研成精密化学株式会社 用于制备甲磺酸艾日布林的中间体以及制备其的方法
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
EP4119563A3 (en) 2017-04-05 2023-04-05 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
CN110831597A (zh) 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗
EP4169924A3 (en) 2017-07-06 2023-07-05 President And Fellows Of Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
WO2019093776A1 (ko) 2017-11-09 2019-05-16 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
US11407762B2 (en) 2017-11-15 2022-08-09 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
IL275729B2 (en) 2018-01-03 2023-09-01 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of helicondrin macrolides and their analogs
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN112437775A (zh) * 2018-07-20 2021-03-02 雷迪博士实验室有限公司 用于制备艾日布林及其中间体的纯化方法
WO2020075027A1 (en) * 2018-10-09 2020-04-16 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
BR112021012138A2 (pt) 2018-12-20 2021-08-31 Auransa Inc. Análogos de pentamidina e seus usos
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US12247239B2 (en) 2019-06-21 2025-03-11 Council Of Scientific & Industrial Research Chemo-enzymatic process for the preparation of homopropargylic alcohol
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
MY209745A (en) 2019-11-07 2025-07-31 Eisai R&D Man Co Ltd Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
JP2023511163A (ja) * 2020-01-22 2023-03-16 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
AU2022316425A1 (en) * 2021-07-22 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Drug conjugate of eribulin derivative
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
WO2024153123A1 (zh) * 2023-01-17 2024-07-25 成都百利多特生物药业有限责任公司 一种艾日布林类药物的偶联物
WO2025081063A2 (en) 2023-10-13 2025-04-17 Eisai R&D Management Co., Ltd. Antibody-drug conjugate metabolites
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
ATE502932T1 (de) 1998-06-17 2011-04-15 Eisai R&D Man Co Ltd Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
EP2522663B1 (en) * 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
SG10201811715YA (en) 2007-10-03 2019-02-27 Eisai R&D Man Co Ltd Intermediates and methods for the synthesis of halichondrin b analogs
EP2220094A1 (en) 2007-11-16 2010-08-25 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
US8203010B2 (en) * 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs

Also Published As

Publication number Publication date
EP2277873B1 (en) 2012-05-30
NO2022019I1 (no) 2022-06-03
ATE502932T1 (de) 2011-04-15
FR11C0038I1 (fr) 2011-10-14
JP2002518384A (ja) 2002-06-25
EP2272839B1 (en) 2012-08-22
CN1216051C (zh) 2005-08-24
NO328280B1 (no) 2010-01-25
CA2632433C (en) 2012-02-07
EP1087960A4 (en) 2004-12-01
US6214865B1 (en) 2001-04-10
PT1087960E (pt) 2011-06-17
FR11C0038I2 (fr) 2013-01-11
LU91854I2 (fr) 2011-10-17
NO2011026I2 (no) 2012-06-11
AU762998C (en) 2000-01-05
HU227912B1 (en) 2012-05-29
CN1312804A (zh) 2001-09-12
NO2011026I1 (no) 2012-01-09
AU4573999A (en) 2000-01-05
BR9911326A (pt) 2001-04-03
EP1087960A1 (en) 2001-04-04
EP2272840A1 (en) 2011-01-12
US6365759B1 (en) 2002-04-02
US8148554B2 (en) 2012-04-03
DE69943296D1 (de) 2011-05-05
DE122011100031I1 (de) 2011-12-15
WO1999065894A1 (en) 1999-12-23
CA2755266A1 (en) 1999-12-23
DK1087960T3 (da) 2011-06-14
CA2632433A1 (en) 1999-12-23
EP2277873A1 (en) 2011-01-26
EP2272839A1 (en) 2011-01-12
CY2011010I1 (el) 2014-04-09
NO2011018I1 (no) 2011-09-26
EP2272840B1 (en) 2012-08-22
NZ508597A (en) 2004-01-30
AU762998B2 (en) 2003-07-10
US20110172446A1 (en) 2011-07-14
NO20093217L (no) 2001-02-15
BR9911326B1 (pt) 2015-01-06
RU2245335C2 (ru) 2005-01-27
ZA200007159B (en) 2001-12-04
JP4454151B2 (ja) 2010-04-21
NO20006316L (no) 2001-02-15
HUP0103357A3 (en) 2002-10-28
CA2755266C (en) 2014-08-12
BE2011C028I2 (en) 2018-08-24
US6469182B1 (en) 2002-10-22
HUP0103357A2 (hu) 2002-01-28
CA2335300A1 (en) 1999-12-23
BRPI9911326B8 (pt) 2021-05-25
NO20006316D0 (no) 2000-12-12
EP1087960B1 (en) 2011-03-23
HK1035534A1 (en) 2001-11-30
KR100798600B1 (ko) 2008-01-28
NO331183B1 (no) 2011-10-24
IL139960A0 (en) 2002-02-10
CA2335300C (en) 2008-10-07
KR20010083050A (ko) 2001-08-31
CY1111516T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
CY2011010I2 (el) Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους
CY2016006I1 (el) Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους
DE69505657D1 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
IS2325B (is) Örgerðar samsetningar epleróns
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
PT1100459E (pt) Preparacao oleosa espumante e sua utilizacao
PT934057E (pt) Formulacoes medicinais de aerossois com formoterol
ID23198A (id) Popok tarik sekali pakai
FI972245A7 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
LV12624A (lv) Thienylazolylalcoxyethanamines their preparation and their application as medicaments
DE69935193D1 (de) Tomografisches Verfahren und System
ID18679A (id) Penggunaan terapi lanjutan
AR027906A1 (es) Uso de agente oftalmico
MX9205721A (es) Metodo de uso y composiciones de win 49596-finasteride
DE69934889D1 (de) Herstellung und reinigung von diboranen
BR9707808A (pt) Composto composição farmacêutica e uso do composto
NO20012011D0 (no) Fremstilling og anvendelse av stivnede oljer
FI964936L (fi) Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
NO20010654L (no) Ny anvendelse av taxoidderivater
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
PT1084126E (pt) Novos derivados de vinca-alcaloides e processos de preparacao
ITMI912290A1 (it) Miscele di n-alchilftalimmidi, loro preparazione e loro impiego
DE69907323D1 (de) Perfluoropolyether-Acylperoxide und deren Herstellung